Safety and Efficacy of Immune Checkpoint Inhibitors Plus Bacillus Calmette–Guérin for High-Risk Non–Muscle-Invasive Bladder Cancer: A Bayesian Re-analysis of a Published Frequentist Meta-analysis
Publication date: Available online 5 November 2026 Source: Clinical Genitourinary Cancer Author(s): Carlos A. Garcia-Becerra, Adel J. El Rassi, Federico Eskenazi, Juan P. Dugarte, Burak Akgul, Rodrigo Guevara Gomez, Maria I. Arias-Gallardo, Jesus E. Juarez-Garcia, Veronica Soltero-Molinar, Luis F. Parra-Camaño, Natalia Garcia-Becerra, Rene Sotelo, Carlos M. Garcia-Gutierrez, Sarmad Sadeghi
Safety and Efficacy of Immune Checkpoint Inhibitors Plus Bacillus Calmette–Guérin for High-Risk Non–Muscle-Invasive Bladder Cancer: A Bayesian Re-analysis of a Published Frequentist Meta-analysis. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1558767326002090?dgcid=rss_sd_all
Safety and Efficacy of Immune Checkpoint Inhibitors Plus Bacillus Calmette–Guérin for High-Risk Non–Muscle-Invasive Bladder Cancer: A Bayesian Re-analysis of a Published Frequentist Meta-analysis. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S1558767326002090?dgcid=rss_sd_all
“Safety and Efficacy of Immune Checkpoint Inhibitors Plus Bacillus Calmette–Guérin for High-Risk Non–Muscle-Invasive Bladder Cancer: A Bayesian Re-analysis of a Published Frequentist Meta-analysis.” Clinical Genitourinary Cancer.
@article{article41183,
title = {Safety and Efficacy of Immune Checkpoint Inhibitors Plus Bacillus Calmette–Guérin for High-Risk Non–Muscle-Invasive Bladder Cancer: A Bayesian Re-analysis of a Published Frequentist Meta-analysis},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1558767326002090?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...